{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:49:46Z","timestamp":1789577386406,"version":"build-2803163510"},"reference-count":106,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Respiratory Medicine"],"published-print":{"date-parts":[[2025,6,3]]},"DOI":"10.1080\/17476348.2025.2490729","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T10:48:41Z","timestamp":1744109321000},"page":"521-533","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Advances and future outlook in clinical trials for treating systemic sclerosis-interstitial lung disease"],"prefix":"10.1080","volume":"19","author":[{"given":"Marzieh","family":"Jamali","sequence":"first","affiliation":[{"name":"University of Michigan Scleroderma Program","place":["Ann Arbor, USA"]},{"name":"University of Michigan Scleroderma Program","place":["Ann Arbor, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Bautista Sanchez","sequence":"additional","affiliation":[{"name":"University of Michigan Scleroderma Program","place":["Ann Arbor, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Agarwal","sequence":"additional","affiliation":[{"name":"University of Michigan Division of Cardiothoracic Radiology","place":["Ann Arbor, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[{"name":"University of Michigan Scleroderma Program","place":["Ann Arbor, USA"]},{"name":"University of Michigan Scleroderma Program","place":["Ann Arbor, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30933-9"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163894"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.149"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.066068"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30144-4"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-022-02292-3"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42861"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41415"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000711"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.2478\/rir-2024-0022"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200706-877OC"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141182"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30318-0"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41153"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac639"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201606-426FR"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez005"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201903-0563CI"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez230"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41020"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25347"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1517\/21678707.2016.1114454"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00909-5"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38702"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.2478\/rir-2024-0023"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0073-2018"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11122293"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003426"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.577739"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-04938-3"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202306-1113ST"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30152-7"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00232-4"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202103-0714OC"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key213"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00359-9"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22204"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055120"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002859"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02071-2022"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41576"},{"key":"e_1_3_5_45_1","article-title":"Combination therapy of mycophenolate mofetil and pirfenidone vs. mycophenolate alone: results from the scleroderma lung study III","volume":"74","author":"Khanna DS","year":"2022","unstructured":"Khanna DS, Bernstein E, Goldin J, et al. Combination therapy of mycophenolate mofetil and pirfenidone vs. mycophenolate alone: results from the scleroderma lung study III. Arthritis Rheumatol. 2022;74. https:\/\/acrabstracts.org\/abstract\/combination-therapy-of-mycophenolate-mofetil-and-pirfenidone-vs-mycophenolate-alone-results-from-the-scleroderma-lung-study-iii\/","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60982-3"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6368"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703327"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02091-9"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223952"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00023-5"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225174"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00282-0"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.06.027"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.891328"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(02)00283-2"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700891"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.03.010"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24129796"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2000665"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.692127"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3612-y"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.24.9739"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2015.07.006"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.22.12999"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7871433"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.3MR0117-033R"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1080\/03008207.2018.1500558"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.10.7243"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac300"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.981738"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.788250"},{"key":"e_1_3_5_73_1","unstructured":"Ingelheim B. A study in people with systemic sclerosis to test whether avenciguat (BI 685509) has an effect on lung function and other systemic sclerosis symptoms (VITALISScE\u2122). Registry name identifier: nCT05559580. [cited 2024 Mar 12]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05559580?cond=Scleroderma&intr=%20Oral%20BI%20685509%20&rank=1#contacts-and-locations"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R046458"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9173090"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S228362"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M113.035600"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.6.168"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00828.x"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-022-01980-4"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.08.1058"},{"key":"e_1_3_5_82_1","volume-title":"Beacon study design: efficacy, safety, tolerability and pharmacokinetics of HZN-825, an LPAR1 antagonist, in diffuse cutaneous systemic sclerosis (abstract)","author":"Khanna d KA","year":"2022","unstructured":"Khanna d KA, et al. Beacon study design: efficacy, safety, tolerability and pharmacokinetics of HZN-825, an LPAR1 antagonist, in diffuse cutaneous systemic sclerosis (abstract). Reykjavik (IS): 21st International Colloquium; 2022."},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.116434"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1523512113"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1177\/23971983241278079"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0206-2022"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2674"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.17303"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201737"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.936182"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126777"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40358"},{"key":"#cr-split#-e_1_3_5_93_1.1","unstructured":"A study of the efficacy and safety of belimumab in adults with systemic sclerosis associated interstitial lung disease (BLISSc-ILD). Registry Name Identifier: NCT05878717. [updated 2024 Apr 12"},{"key":"#cr-split#-e_1_3_5_93_1.2","unstructured":"cited 2024 Dec 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05878717?cond=Scleroderma&term=belimumab&rank=2"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1624463"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-76987-6"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102364"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150326"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000907"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38288"},{"issue":"8","key":"e_1_3_5_100_1","first-page":"1635","article-title":"A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to determine the effectiveness of the type I interferon receptor antibody, anifrolumab, in SYstemic sclerosis: DAISY study design and rationale","volume":"42","author":"Khanna D","year":"2024","unstructured":"Khanna D, Denton CP, Assassi S, et al. A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to determine the effectiveness of the type I interferon receptor antibody, anifrolumab, in SYstemic sclerosis: DAISY study design and rationale. Clin Exp Rheumatol. 2024;42(8):1635\u20131644.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39501"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202312-2213SO"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00052-8"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1017-7"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3664-1"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02548-1"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38101"}],"container-title":["Expert Review of Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17476348.2025.2490729","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T18:18:56Z","timestamp":1751566736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17476348.2025.2490729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":106,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,3]]}},"alternative-id":["10.1080\/17476348.2025.2490729"],"URL":"https:\/\/doi.org\/10.1080\/17476348.2025.2490729","relation":{},"ISSN":["1747-6348","1747-6356"],"issn-type":[{"value":"1747-6348","type":"print"},{"value":"1747-6356","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierx20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierx20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-01-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}